UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102, UGN-103 which is in phase 3 of clinical trial for intravesical solution, and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Period	TotalRevenue
2017-12-31	$8.16M
2018-12-31	$1.13M
2019-12-31	$18.00K
2020-12-31	$11.80M
2021-12-31	$48.04M
2022-12-31	$64.36M
2023-12-31	$82.71M
2024-12-31	$90.40M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	URGN	$18.82	+0.00%	0.38M
3
4
5

UroGen Pharma Ltd. (URGN) Revenue History

Revenue Data

Get UroGen Pharma Ltd. Data in Excel

More URGN Financial Data